{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-26-000041","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2026-05-12T20:10:14+00:00","discovered_at":"2026-05-12T20:11:00.300712+00:00","generated_at":"2026-05-12T21:22:01.267663+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zentalis Q1 2026 cash $211.8M; selects pivotal azenosertib dose; DENALI readout by year-end","bullets":["Cash, cash equivalents and marketable securities $211.8M as of March 31, 2026; provides runway into late 2027.","Selected 400mg QD 5:2 as pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC based on DENALI Part 2a interim.","DENALI Part 2 topline readout expected by year-end 2026; potential accelerated approval pathway.","ASPENOVA Phase 3 confirmatory trial in Cyclin E1-positive PROC initiated with first patient dosed.","Q1 total operating expenses $37.9M, down from $45.6M (includes $7.8M non-recurring restructuring in prior year)."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-26-000041","json":"https://secwatch.observer/filing/0001725160-26-000041.json","markdown":"https://secwatch.observer/filing/0001725160-26-000041.md","text":"https://secwatch.observer/filing/0001725160-26-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000041/0001725160-26-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000041/zntl-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:22:01.267663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a426b1af09c3194aea1ae43e873f01fb593677c0","claim":"Zentalis Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 12, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000041/0001725160-26-000041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}